FABP4 blocker attenuates colonic hypomotility and modulates white adipose tissue-derived hormone levels in mouse models mimicking constipation-predominant IBS

Background The role of fatty acid binding protein 4 ( FABP 4) in lower gastrointestinal ( GI ) motility is unknown. We aimed to verify the effect of inhibition of FABP 4 on GI transit in vivo, and to determine the expression of FABP 4 in mouse and human tissues. Methods Fatty acid binding protein 4 inhibitor, BMS 309403, was administered acutely or chronically for 6 and 13 consecutive days and its effect on GI transit was assessed in...